Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Fineline Cube Jun 18, 2026
Company Deals

Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline

Fineline Cube Jun 18, 2026
Company Deals

Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia

Fineline Cube Jun 18, 2026
Company Deals

Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline

Fineline Cube Jun 18, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success

Fineline Cube Jun 22, 2026
Company Drug

Hotgen Biotech Secures NMPA Approval for SGT003 Bispecific Antibody Targeting Tumor Microenvironment

Fineline Cube Jun 18, 2026
Company Deals

Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib

Fineline Cube Mar 2, 2023

Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase...

Company

Zai Lab Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 2, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...

Company Deals

Pengyang Yiliao Raises Series B+ Funds for Cardiovascular Product Development

Fineline Cube Mar 2, 2023

Pengyang Yiliao, a Beijing-based developer and manufacturer of cardiovascular technology, has reportedly raised “tens of...

Company Drug

Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study

Fineline Cube Mar 2, 2023

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III...

Company Deals

Glowe Raises Series A+ Funding to Expand AIGC in Mental Health

Fineline Cube Mar 2, 2023

Glowe, an online psychological consultation platform based in Guangdong, has reportedly raised “tens of millions”...

Company Deals

Geneus Tech Secures Funding for Gseq500 Gene Sequencer Production

Fineline Cube Mar 2, 2023

Geneus Tech, a Shenzhen-based developer and manufacturer of gene sequencers, has reportedly raised an undisclosed...

Company Deals

Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development

Fineline Cube Mar 2, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...

Company Drug

CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia

Fineline Cube Mar 2, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...

Company Deals

BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results

Fineline Cube Mar 1, 2023

BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...

Company

Viatris Reports Q4 2022 Results, Highlights China Growth

Fineline Cube Mar 1, 2023

US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The...

Company Medical Device

China Performs First AB-BNCT Procedures Outside Japan

Fineline Cube Mar 1, 2023

The first accelerator-based boron neutron capture therapy (AB-BNCT) procedures have been performed in China by...

Company

HutchMed Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 1, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the...

Company Drug

3SBio’s Nalfurafine Tablets Accepted for Review by NMPA for Chronic Liver Disease

Fineline Cube Mar 1, 2023

China-based 3SBio Inc. (HKG: 1530) has announced that a clinical trial filing for its nalfurafine...

Company Deals

3SBio Terminates Distribution Agreement with AstraZeneca for Byetta

Fineline Cube Mar 1, 2023

China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK...

Company Drug

JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma

Fineline Cube Mar 1, 2023

China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...

Company

FibroGen Reports Q4 2022 Financial Results with Revenue Growth

Fineline Cube Mar 1, 2023

US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global...

Policy / Regulatory R&D

China Issues New Ethical Review Measures for Life Sciences and Medical Research

Fineline Cube Mar 1, 2023

The National Health Commission, Ministry of Education, Ministry of Science and Technology, and National Administration...

Company

Bayer Reports 2022 Sales Growth, Highlights New Drug Performances

Fineline Cube Mar 1, 2023

Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales...

Policy / Regulatory

China’s NRDL Update and Expansion of ‘Dual Channel’ Drug Access

Fineline Cube Mar 1, 2023

The latest update to China’s National Reimbursement Drug List (NRDL) was implemented from March 1,...

Policy / Regulatory

China’s State Council Unveils Plan for TCM Revitalization and Development

Fineline Cube Mar 1, 2023

The State Council has released the “Traditional Chinese Medicine (TCM) Revitalization and Development Major Projects...

Posts pagination

1 … 576 577 578 … 685

Recent updates

  • Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)
  • Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success
  • Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases
  • UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases
  • Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)

Company Drug

Johnson & Johnson Secures Second NMPA Approval for Akeega in BRCA2-Mutated Metastatic Prostate Cancer Following AMPLITUDE Trial Success

Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.